<DOC>
	<DOCNO>NCT00873808</DOCNO>
	<brief_summary>RATIONALE : Gathering information time image laboratory test woman receive bisphosphonates breast cancer may help doctor learn long-term bone quality plan best treatment . Tetracycline hydrochloride demeclocycline hydrochloride mark new growth bone , may see good microscope . PURPOSE : This clinical trial study long-term bone quality woman breast cancer enrol clinical trial SWOG-S0307 .</brief_summary>
	<brief_title>S0307A , Long-Term Bone Quality Women With Breast Cancer Enrolled Clinical Trial SWOG-S0307</brief_title>
	<detailed_description>OBJECTIVES : - To assess long-term high-dose bisphosphonates alter bone quality measure change histomorphometry bone biopsy tetracycline hydrochloride label calculate erode osteoid surface , mineralization surface , bone formation rate , wall width , activation frequency . - To assess long-term high-dose bisphosphonates alter bone quality measure change backscatter electron image bone measure average mineralization density well distribution density value . - To assess long-term high-dose bisphosphonates alter bone quality measure change micro-computed tomography bone biopsy specimens measure bone structure , include bone volume , connectivity , trabecular width , cortical width . - To assess long-term high-dose bisphosphonates alter bone quality measure change biomechanical test bone biopsy sample load compression measure stress-strain relationship , include Young 's modulus , yield point , ultimate strain , work failure ( toughness ) . - To characterize bone use classical , non-invasive technique ( i.e. , measurement bone mineral density spine hip use dual energy x-ray absorptiometry analysis serum biochemical marker bone formation [ i.e. , bone specific alkaline phosphatase ] resorption [ i.e. , N-telopeptide ] ) long-term , high-dose bisphosphonates . OUTLINE : This multicenter study . At baseline ( prior initiate bisphosphonate therapy SWOG-S0307 ) , patient receive oral tetracycline hydrochloride twice daily day 1 2 oral demeclocycline hydrochloride twice daily day 11 12 . Patients undergo tetracycline hydrochloride-labeled bone biopsy anterior ilium day 14 . At 36 month ( patient complete bisphosphonate therapy ) 30 month concurrent bisphosphonate therapy , patient receive oral demeclocycline twice daily day 1 2 oral tetracycline hydrochloride twice daily day 11 12 . Patients undergo demeclocycline hydrochloride-labeled bone biopsy anterior ilium day 14 . Patients undergo dual energy x-ray absorptiometry measurement hip spine time biopsy within next 10 week . Blood sample collect analysis bone specific alkaline phosphatase N-telopeptide treatment clinical trial . After completion study treatment , patient follow 10 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Clodronic Acid</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<mesh_term>Demeclocycline</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Concurrently enrol clinical trial SWOGS0307 receiving bisphosphonates adjuvant therapy primary breast cancer No rickets , osteogenesis imperfecta , osteosclerosis , osteomalacia No bone fracture since age 21 year unless cause trauma Hormone receptor status specify PATIENT CHARACTERISTICS : Menopausal status specify Weight &lt; 300 lb No hyperparathyroidism No serious concurrent prior anorexia nervosa diagnose physician cause abnormal menstruation No history hypersensitivity tetracycline demeclocycline PRIOR CONCURRENT THERAPY : See Disease Characteristics More 10 year since prior prednisone dose 5 mg/day â‰¥ 3 month No prior prednisone diagnosis breast cancer No prior bisphosphonate therapy No concurrent anticonvulsant medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>breast cancer</keyword>
</DOC>